A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2019
Price : $35 *
At a glance
- Drugs G 305 (Primary) ; Glycopyranosyl lipid adjuvant
- Indications Advanced breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Sarcoma; Synovial sarcoma
- Focus Adverse reactions; First in man
- Sponsors Immune Design
- 01 Jul 2019 Results published in the Cancer Immunology Immunotherapy
- 15 Aug 2017 Status changed from active, no longer recruiting to completed.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.